-
Have other known disease-causing mutations documented in the participant's medical history or identified through a retinal dystrophy gene panel that, in the opinion of the Investigator, would interfere with the potential therapeutic effect of the study drug or the quality of the assessments
-
For participants with herpes simplex virus (HSV):
- Have a history of oral or genital herpes and be unable and/or unwilling to use a prophylactic antiviral medication.
- Have a history of ocular herpes.
- Have active oral or genital herpes or are currently receiving treatment for active HSV infection
-
Have complicating systemic diseases (e.g., medical conditions causing immunosuppression, autoimmunity, active systemic infection) that would preclude the gene transfer or ocular surgery if not adequately managed or treated
-
Have a known sensitivity or allergy to systemic corticosteroids or other immunosuppressive medications
-
Have used anticoagulant agents that may alter coagulation (e.g., warfarin, heparin, apixaban, or high-dose docosahexaenoic acid [fish oil]) within 7 days prior to study drug administration (ibuprofen, aspirin, or similar agents are acceptable
-
Have received any vaccination/immunization within 60 days prior to Day 1 and/or during screening with the exception of the influenza vaccine, which is only exclusionary if received within 28 days prior to Day 1
-
Have used systemic corticosteroids or other immunosuppressive medications within 3 months prior to study drug administration. Corticosteroids used on an as-needed basis administered by insufflation, inhalation, or local administration to the skin and mucosa such as Symbicort® (budesonide/formoterol), Flonase® (fluticasone propionate), and skin creams and ointments containing corticosteroids shall not be exclusionary
-
If sexually active or planning to become sexually active, are unwilling to use barrier contraception for 3 months following study drug administration
-
Have any other condition or reason that, in the opinion of the Investigator, would prevent the participant from completing all study assessments
-
Have any other condition or reason that, in the opinion of the Investigator, makes the participant unsuitable for the study
-
Are currently participating or recently participated in any other research protocol involving investigational agents or therapies that, in the opinion of the Investigator, would make the participant unsuitable for the study. Recent participation is defined as participation within 90 days of initial screening for this study OR within 10 half-lives of the investigational drug, whichever is longer
-
Have previously received any adeno-associated virus (AAV) gene therapy product, stem cell therapy, cell-based therapy, or similar biologics
